Announces three-year business strategy and commercial growth drivers, targeting up to 10% revenue growth in 2026 Expects to expand seasonal vaccine franchise from three to up to six approved products ...

Received FDA IND clearance to evaluate CDI-988 as both norovirus preventive and treatmentExpects to initiate CDI-988 Phase 1b ...

COCP READ THE FULL COCP RESEARCH REPORT Business Update Phase 1b Challenge Study of CDI-922 to be Initiated in 1H26 Cocrystal Pharma, Inc. (NASDAQ:COCP) is developing CDI-988 as a prophylaxis and ...

First, the phase 3 trial of Moderna’s norovirus vaccine had to endure a clinical hold. Now, the study has to head back for a second season in the Northern Hemisphere after failing to find enough cases ...

Entered into an exclusive license agreement with Dynavax for the Company’s COVID-19 oral pill vaccine candidate for potential cumulative proceeds ...

Q3 2025 Earnings Call Transcript November 13, 2025 Vaxart, Inc. beats earnings expectations. Reported EPS is $-0.04, ...

Announces three-year business strategy and commercial growth drivers, targeting up to 10% revenue growth in 2026Expects to expand seasonal vaccine franchise from three to up to six approved products b ...

Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51) Narrows 2025 projected ...

We expect to begin enrolling participants in the first quarter of 2026 for our norovirus challenge study evaluating CDI-988, our oral ...

Many hungry travelers turn to airport grab-and-go food before flights, but if you want to avoid getting sick before hopping ...

Six people have died due to an outbreak of listeria linked to prepared pasta meals sold at major US grocery chains. A doctor ...